SE TAIRE "NÉGLIGENCE CRIMINELLE" / TO REMAIN SILENT "CRIMINAL NEGLIGENCE" / CODE OF SILENCE"À COEUR OUVERT / WITH OPENED HEART" / MICHELINE & TONY'S ARTICLES
![]()

IMPLANTS AMERS / IMPLANTS MAUDITS !
MY BREAST IMPLANT / MY WORST NIGHTMARE

![]()
US PANEL RECOMMENDS ADDING ESTROGEN TO CANCER
Date: Sat, 16 Dec 2000 16:04:23 -0800 (PST)
From: ruby rahn
rubyrm@yahoo.comDecember 15, 2000
US Panel Recommends Adding Estrogen To Cancer List
Dow Jones Newswires
WASHINGTON (AP)--A panel of scientific advisers says estrogen should be placed on the U.S. list of cancer- causing substances, even though it remains a good treatment for many women.
The National Toxicology Program advisory committee voted 8-1 that steroidalestrogen - a type used in post- menopausal treatments and birth control pills - should be listed because of an association with endometrial cancer and, to a lesser extent, breast cancer.
Another type of post-menopausal estrogen, conjugated estrogens, already is on the federal carcinogen list.
Doctors already know about the cancer link. That's the reason post-menopausal estrogen is given together with another hormone called progestin - the combination lowers the risk of endometrial cancer.
But the NTP advisers said putting all estrogens on the federal list would help women trying to balance the benefits and risks when choosing hormone therapy.
"Physicians never discuss any of these risks when they are prescribing hormone therapy. They only discuss benefits. Listing might force it on the table," said Michelle Medinsky, a toxicologist from Durham, N.C., before the vote.
The committee of scientists advises the NTP, a branch of the National Institutes of Health that every two years updates the federal list of proven and suspected cancer-causing substances. The NTP typically follows its advisers' recommendations, but an officially updated carcinogen list isn't expected until 2002.
Thursday, the panel declined to add talc powder to the list, saying there wasn't enough evidence linking its use in feminine hygiene products to ovarian cancer. The panel deadlocked over whether to list a second type of talc, fibrous talc that some studies have linked to lung cancer in talc miners.
On Wednesday, the panel voted to add ultraviolet radiation - those sunburn-causing rays long known to cause skin cancer - to the official carcinogen list.
DONOR PLASMAPHERESIS
A CONTREVERSIAL ISSUE
IN BLOOD COLLECTION
The Blood Trail Part 1 & The Blood Trail
Most people who have written about the early origin of the H1V and hepatitis blood candals of the early-eighties have not taken into consideration the role of blood collection technology.
The key but forgetten element is donor plasmapheresis. These techniques originated primarily for therapeutic applications in the late-sixties. They are high risk procedures and met with severe complications from the outset. However, their applications were justified because of the severity of the diseases they addressed (including leukemia). Early participants in this technology included a precursor to Baxter, then known as Travenol/Aminco.
Early commercial devices for plasmapheresis included crude on-line blood separators derived from the Sorvall patents on milk separators. These machines were widely sold hospitals. Their primary problems were the rotor and and the rotary fluid seal assemblies which were not disposable. These expensive and complex parts would shed abraded debris. They required manual disassembly and elaborate cleaning procedures followed by reassembly. Exhaustive sterelization was needed between each use. These processes required skilled technitians and much time. This was not technologically feasible under hurried clinical conditions.
Several of these machines are still in use, albeit for speciallized therapeutic applications, later variations of commercially made plasma separation devices had on-line versions and these found widespread usage in the blood banking industries. They were encoutered extensively in the San Francisco and Oakland blood collection centers, even in the early- eighties. They had major problems of sterility and solid particulates contamination control.
Valuable "frequent donors" were often pressured to join plasmapheresis programs. The programs were promoted as state-of-the-art technologies of great merit without special risks that allowed blood donations as frequently as several times at month. Contractors with facilities in penal institution collections programs used it almost universally up to the late-nineties. The Red Cross, bayer, Connaught and Cutter also depended on these programs for collection of donor blood streamed into commercial blood fractionation plants, as did the association of the independent American Blood Bank and the other contractor-type blood collection agencies such as Cryosan/Continental Pharma.
Continental Phama (CCP) later emerged as a major factor in contaminated blood supplies. It affected mostly non-U.S. bulk blood product purchasers, specifically Canadian blood agencies. CCP had contracts for blood collection from inmates at Arkansas penal institutions and sold bulk blood products to American processors for resale abroad. CCP had poor control over the collection process and may have infringed on basic requirements on the use of plasmapherisis equipment. In the mid-nineties, CCP records were investigated and the agency figured prominently in a Canadian blood coandal. Their blood-derived products were identified as high infection risk material, specifically with HIV and hepatitis.
CCP and other similar agencies depended strongly or rapid low cost blood collection techniques which made use the same donors. Plasmapheresis was an essential element in the economic viability of the program.
During high volume blood/plasma collection via plasmapheresis, there is simultaneous separation of the principal blood componement. The unwanted red cells are returned to the donor either as a separate step at the session (called manual plasmapheresis) or as an integral part of the collection procedure (on-line plasma separation). The donor may remain connected to a separation device for several hours as blood is processed and the red cells are reinfused through a separate line or through a single but concentric needle/cannulae system.
Plasmaperesis requires drugs to facilitate separation of minority components. Typically, steroids like SoluMedrol are given to facilitate aglomeration of certain fractions. Incidental to processing, the incoming blood must be mixed with anticoagulants. The most common preparation is the citrate buffer. This solution dilutes the blood to facilitate the separation process and the coagulant is then reinfused into the user. Alternate anticoagulants such as heparin are considered too costly and are employed only in certain types of therapeutic plasmapheresis. These various additives are belleved to be compatible and necessery for situations where more frequent donations are wanted and where the selected blood fraction is to be optimized (increased yield or boosted plasmapheresis).
These techniques also reduce the overall cost of processing the donor blood, a factor of particular significance in commercial blood collection. In spite of widespread usage amongst healthy and voluntary donor populations, many of whom were individuals with rare blood types, the technology was not well mastered. Complications were not resolved leading to disengagement in the eighties of several firms from the field.
The techniques were then and are still controversial. The community fluent with the blood industry believes that misuse of this technology and the indiscriminate application of poorly controlled plasmapheresis systems, mishandled by improperly trained staff and unethical practices by some of the collection agencies contributed dramatically to the spread of blood-borne diseases in the eighties, in particular non-A and non-B hepatitis. Other problems unrelated to infection but derived from solid and fluid impurities entrained from the equipment which terminated in the donor remain unaddressed of this day.
U.S. SAYS INFANT RESPIRATORY VIRUS SPREADING..our babies
Date: Mon, 11 Dec 2000 16:04:10 EST
From: ParfumGigi@aol.com
To:
SBI-Talk@egroups.comMy gift from God, my sweet G. Baby had this, and we almost lost him. He had been at the pediatricians, earlier that day, it only takes a moment to become critical. Please pass this on, children are so precious, and completely innocent...they depend on us *
gigi/Karen
U.S. SAYS INFANT RESPIRATORY VIRUS SPREADING
Outbreaks of a potentially dangerous respiratory infection that attacks infants are becoming widespread as winter approaches, U.S. health experts said Thursday. The Centers for Disease Control and Prevention said it was concerned about the spread in recent weeks of respiratory syncytial virus, the most common cause of pneumonia and bronchiolitis, a severe infection of the breathing tubes, in infants.
STUDY LINKS INTESTINAL BACTERIA TO IRRITABLE BOWEL SYNDROME
Study links intestinal bacteria to irritable bowel syndrome
Date: Wed, 13 Dec 2000 21:45:01 -0800
From: "Myrl Jeffcoat"
myrlj@jps.netDecember 13, 2000
Web posted at: 11:19 AM EST (1619 GMT)
LOS ANGELES, California (Reuters) -- Irritable bowel syndrome, a chronic condition believed to plague 20 percent of the adult population in developed countries, may be caused by too much bacteria in the small intestine, researchers said Wednesday.
It was the first time a potential cause for the disease has been identified and could lead to a radical shift in treatment, according to the lead investigator in the study.
"This is really exciting because it points to the cause of the disease. Treatments for irritable bowel syndrome (IBS) to this point have been directed at symptoms, not any cause," said Dr. Mark Pimentel, who is also assistant director of the gastrointestinal motility program at Cedars-Sinai Medical Center in Beverly Hills, California.
Symptoms of IBS, which is diagnosed in twice as many women as men, include gas, bloating, abdominal pain, constipation and diarrhea.
"We found that 78 percent of IBS patients have bacterial overgrowth in the small intestine. Antibiotics got rid of the disease in half of the patients that got rid of the overgrowth," Pimentel said.
Treatments for the gastrointestinal condition currently range from anti-depressants, which are supposed to alter nerve endings in the abdomen, to advice to eat more fiber in order to alleviate constipation.
Last month, the IBS drug Lotronex was pulled from the market by its maker Glaxo Wellcome after the U.S. Food and Drug Administration voiced concerns about side effects and said three deaths might have been related to the product.
Lotronex, marketed as a treatment for women with diarrhea-predominant IBS, was linked to reports of a bowel condition called ischemic colitis, which restricts blood flow to the colon. Some Lotronex users also reported severe complications from constipation.
Zelmac, an experimental drug described as a treatment for women with constipation symptoms of IBS, is expected to be approved by the FDA and launched by its maker Novartis AG by the middle of next year.
But Pimentel said pharmaceutical companies may want to redirect their research efforts to target alternatives for eradicating bacteria in the small intestine.
"Once they see this trial, they will really wonder what they're doing," Pimentel said.
Cedars-Sinai investigators evaluated 202 patients who underwent a specialized breath test to determine the presence of small intestinal bacterial overgrowth, a condition in which bacteria typically found in the colon makes its way up into the small intestine.
"The bacteria produces the bowel symptoms. The fact that we found the overgrowth in almost 80 percent of patients with IBS is quite dramatic," Pimental explained.
He noted that there are several mechanisms designed to prevent the build-up of bacteria in the small intestine, but researchers do not know what goes wrong to allow the bacteria to accumulate.
Participants in the study were treated for 10 days with antibiotics, which eliminated signs of the disease in 25 of the 47 patients who returned for follow-up exams. Treatment with alternative antibiotics has been effective in about 90 percent of patients at the Cedars-Sinai clinic, Pimental said.
Of the 25 study patients in which no small intestine bacteria was detected after treatment with antibiotics, 12 reported no symptoms of IBS and 13 reported significantly reduced symptoms, the researchers said.
"We are concerned about overtreatment with antibiotics and potential resistance to antibiotics. We are currently studying other therapies for eliminating the bacteria, but the results so far are not objective," the Cedars-Sinai doctor said.
The Cedars-Sinai team, which published its study results in the December issue of The American Journal of Gastroenterology, is currently conducting a double-blind study comparing treatment with antibiotics to placebo in IBS patients.
PETITES FLEURS QUÉBEC TÉMOIGNAGES 2000
TESTIMONIES LITTLE FLOWERS 2000
BREAST IMPLANTS, SILICONE VICTIMS VERY SICK!
TÉMOIGNAGES QUÉBEC / ARTICLES SANTÉ FRANÇAIS/ENGLAIS
IMPLANTS SALINS URGENT! APRÈS 1992! SALINE IMPLANTS AFTER 1992!
Charles Cantin Avocat /Cantin & Perron &Ass.
À VOUS TOUS /TO ALL OF YOU
"TO REMAIN SILENT IN THE FACE OF ALL THIS DOUBT, IS TANTAMOUNT TO CRIMINAL NEGLIGENCE"
"SE TAIRE LORSQUE L'ON FAIT FACE À TANT DE DOUTE RELÈVERAIT DE LA NÉGLIGENCE CRIMINELLE"
EN MÉMOIRE DE NOS PETITES FLEURS
IN MEMORY OF OUR LITTLE FLOWERS
SUICIDE FROM A PLASTIC SURGEON "HOUSTON "
AS PIERRE BLAIS Ph.D said to me yesterday he was a wonderful and respectable plastic surgeon. "Question? Why this wonderful doctor KILL HIMSELF by suicide! Horrible death and how many are in this death situation? A really good doctor has to stop the massacre!
MAY GOD OPEN EYES TO BLIND PEOPLES!
QUE DIEU OUVRE LES YEUX AUX GENS AVEUGLES !
"IMPLANTS MAMMAIRES""BREAST IMPLANTS"
UN AUTRE CHIRURGIEN PLASTICIEN SUICIDÉ! IL ÉTAIT UN REMARQUABLE CHIRURGIEN PLASTICIEN TRÈS RESPECTABLE ET CONSCIENCIEUX .
À CŒUR OUVERT / WITH OPENED HEART "Micheline"
Un petit mot pour vous remercier de votre support . La situation est alarmante car de plus en plus de victimes et de moins en moins de l'écoute de nos médecins.
Car voyez-vous en admettant que les implants mammaires causent des problèmes de santé des billions $$$ seront perdus dans ce monde dont le pouvoir financier est plus important que la santé.
Je vous invite donc, à contacter Me.Cantin et Me.Maltais qui sont disponibles à vous écouter et vous aider. Il y a urgence pour les porteuses d'implants salins de ommuniquer avec nos avocats et en urgence pour protéger votre santé.
Bonjour ,
Je m'appelle "Petite Fleur" , je suis de la province de Québec. Je peux comprendre les problèmes que les femmes ont au sujet du silicone. J'ai été infecté par la silicone assez jeune. J'avais 19 ans quand je me suis fait opérée pour augmentation mammaire. Depuis ce temps là , il m'arrive toutes sortes de symptômes que le médecin ne comprend pas toujours. Il croit que c'est dans ma tête. Mais moi je sais que c'est pas normal car j'ai tout essayé ce qu'ils m'ont donné et je ne remonte pas la pente. Je suis toujours fatiguée, j'ai toujours de l'inflammation a l'intérieur et en plus cela me cause des problèmes respiratoires , comme de l'asthme mais j'ai passé des tests et je n'ai pas l'asthme mais encore là ils n'ont rien vu le pourquoi de mes problèmes de respiration. J'ai arrêté de fumer depuis 10 ans et mes problèmes persistent. J'ai eu des douleurs articulaires pendant des années ,cela brulait comme du feu (pendant au moins 3 ans ) très intense. et puis du jour au lendemain les brulures ont parti? J'ai eu des infections urinaires a répétitions .J'ai eu beaucoups d'antibiotiques. Mes anticorps anti-nucléaire ont été positif . A cause de mes problèmes respiratoires j'ai été opéré pour le nez 4 fois mais sans résultats.Le coté inflammation persiste et au niveau des bronches et des fois je sens qu'il y a du liquide a l'intérieur.
Les médecins ne comprennent pas mes symptômes. J'ai eu une mononucléose adultes, kystes sur les ovaires, utérus, thyroide (sans que ce soit cancéreux) endométriose , jaunisse etc. Je ne trouve pas cela normal que cela nepersiste. J'ai fait enlever mes prothèses cela fait maintenant 5 ans et puis mes symptômes persistent . J'ai oublié de dire qu'en faisant enlever mes prothèses ils ont découvert qu'elles étaient déchirées. J'ai hâte d'avoir le bout du tunnel. Je vais avoir 46 ans en décembre. J'ai porté mes prothèses pendant 20 ans à peu près.
Continuez votre beau travail.
J'ai trouvé votre site par hazard et j'en suis très contente.
Petite Fleur Québec
Je lance un appel de détresse à tous les médecins et avocats et à nos gouvernements pour agir devant tant de victimes et de souffrances. Comment peut-on rester sans agir dans la situation présente et même continuer à encourager de telles chirurgies.
Il faut l'ouverture d'un centre crédible sur la recherche pour un implant sécuritaire et pour la sécurité de tout instrument médical et produits de santé.
It is a call detress to all medical world and world governments and world lawyers to help people to have medical care an research on safe devices concerning our health.
UNE BOMBE À RETARDEMENT
Dans le cas d'une bombe, une minuterie électronique détermine le temps précis devant s'écouler entre le moment de la mise en place et celui de l'explosion. Malheureusement, cela ne s'applique pas aux prothèses mammaires de gel de silicone.
En 1963, le P' Thomas Cronin de Houston, présenta, l'implant mammaire de gel de silicone Dow Corning, à la Société internationale des chirurgiens plasticiens, il qualifia la silicone de corps tout à fait inerte. Il affirma que dans un cas de rupture d'implant , le gel de silicone ne migrerait pas et que le gel libéré ne serait pas nocif pour les tissus. Cronin ajouta: "tel que scientifiquement prouvé par Dow Corning". Les plasticiens crurent donc que les implants mammaires de silicone dureraient toute une vie.
Quelques années plus tard seulement, on rapportait des ruptures d'implants et vers 1978, D' Thomas Biggs de Houston, admit un taux de ruptures spontanées de 17%. Après une étude approfondie de la force structurale de ces implants, le D' Mike Resh, ingénieur mécanique, témoigna devant la FDA en février 1992, que les implants étaient conçus pour durer de 5 à 7 ans. Depuis que les changements structuraux et chimiques furent apportés, au fil des ans, à la fabrication de ces implants, on ne peut prévoir leur potentiel réel de longivité. En d'autres termes, une femme porteuse de prothèses mammaires en gel de silicone devrait s'attendre à une rupture à tout moment. Bien sûr, l'imprévisibilité alimente les craintes de la patiente.
Un implant se compose de trois éléments de base:
1 Une enveloppe d'élastomère de silicone (aussi appelée caoutchoux de silicone), physiquement, c'est une membrane semi-imperméable.
2 Du gel de silicone, chimiquement c'est un lacis tridimentionnel de silicone solide retenant de la silicone liquide; physiquement, le gel est un état intermédiaire entre l'état solide et liquide.
3 La silicone liquide correspondant à un volume de 55% à 95% de gel Conclusion: Les victimes de ces implants on des problèmes de santé!
" Le Scandale Derrière Les Implants Mammaires Henry Jenny Chirurgien Plasticien"
THE TIME BOMB
In a bomb, an electronic clockwork determines the precise time period that will elapse between the planting of the bomb and its explosion. Unfortunately, this is not true for the silicone gel implants. When, in 1963, Professor Thomas Cronin of Houston introduced the Dow Corning silicone gel-filled breast implant to the international Society of Plastics Surgeons, he called the silicone a totally inert material. He stated that in case of implant rupture, the silicone gel would not migrate and that free gel would not be harmful to tissue. Then Cronin added "as scientifically, proven by Dow Corning." Consequently, it was also believed by most plastic surgeons that the silicone breast implants would last for ever.
It was to be only a few years later that implant ruptures were rapported in 1978, Dr.Thomas Biggs from Houston admitted to a spontaneous rupture rate of 17&. After studying the structural strength of these implants in depth, Dr. Mike Trsh, a mechanical engineer, gave testimony before the FDA in February, 1992, that implants were designed to last between 5 to 7 years. Since structual as well as chemical changes were made in the production of these implants over the years, their exact life expectancy cannot be predicted. In other words, a woman with silicone gel-filled breast implants should expect a possible rupture at any time. Understandably, it is unpredictability wich aggravates the patient's fear.
An implant consists of three basic components:
1 An envelope made of a silicone elastomer also referred to a silicone rubber. Physically this is a semi-permeable membrane.
2 Silicone gel that chemically is a three dimensional network of solid silicone holding liquid silicone . Physically a gel is an intermediate stage between solid and liquid.
3 The liquid silicone which represent 55% to 95% of the gel. Conclusion: The breast implants victims have health's problems.
"Silicone -Gate Exposing The Breast Implant Scandal Henry Jenny M.D."
TÉMOIGNAGES PHOTOS/ TESTIMONIES PHOTOS
Case Study of Dow Corning
University of Phoenix
Ed Santana
Paula Rogers
Joe Timassy
Diane Zapien
Jessica Mercado
Julie K. Garcia
SOC/101
Lauren Moulton-Beaudry
11/13/00Dow Corning
When breast implants were first introduced as early as 1940 they were largely inregulated, even though thousands of women a year were using them to enlarge their breast or reconstruct them after a mastectomy. In the early 1940’s Japanese prostitutes had their breast injected with substances such as paraffin, sponges and non-medical grade silicone to enlarge their breasts. One of the reasons is that Japanese women felt American servicemen favored women with large breasts.
Originally in the early 60’s, as noted, they were used for the most part to reconstruct breasts after mastectomy surgery. When the 70’s era came breast implants were used by movie stars to enhance their looks for television and thus a trend started. Breast implants were no longer a "surgical procedure" but now a new type of surgeon came to be and that was the "cosmetic surgeon". Now breast implants were part of the procedure, which included tummy tucks, face-lifts, and lip enhancements for people of all walks of life. In the 1960’s two plastic surgeons from Texas: Frank Gerow and Thomas Cronin developed silicone filled implants which were more natural feeling and able to be shaped easier. Reports of adverse reactions to breast implants, especially silicone-filled implants, began accumulating in the Food and Drug Administration files. The FDA finally asked implant manufacturers to submit evidence of their products, however implants were allowed to remain in the marketplace despite the lack of studies.
In April of 1992 implants were ordered off the market, however, the FDA never said they were unsafe; it only said that studies did not exist to provide evidence of how safe they were. This action occurred in the wake of several successful lawsuits against breast implant manufactures.
Some of the Chronology of breast implants:
1940 Japanese prostitutes have their breast injected with substances such as paraffin, sponges and non grade silicone to enlarge breasts for American servicemen.
1960 the first silicone breast implants are developed by Two plastic surgeons from Texas: Frank Gerow and Thomas Cronin.
1962 Timmie Jean Lindsey becomes the first woman to receive silicone breast implants.
1976 The Food and Drug Administration enacts the Medical Devices Amendment to the Food and Cosmetic Act. But for 15 years breast implants are "grandfathered" to require proof of safety and effectiveness.
1988 The FDA finally announced that breast implants manufactures would have to subit evidence of safety and effectiveness of the implants.
1990 T.V reporter Connie Chung interviewed women who claimed to have disease and cancer caused by implants. She made her view that implants were dangerous devices and thus started advocacy groups, consumer groups and public awareness.
It was in 1972 when Dow Corning’s breast implant business started to experience problems and was faced with a serious competitive threat. Five of the companies scientists left and went to a competitor, where they used their experience with silicones to develop a competitive breast implant. A few years later the same men left this company and took the knowledge and expertise they had gained from both companies and started their own company called McGhan Medical. By 1974 Dow Corning had competition in the market place.
It wasn’t long when the new implants that McGhan Medical had developed had quickly gained favor in the market place because the implant was much softer, more responsive and almost an exact match to the natural breast. It was at this time that Dow’s marketshare began to decline and problems began to occur.
Dow immediately put together a special task team to develop a new generation of breast implants. Because of the decline in the market place that Dow was experiencing, the team opted to cut corners and go without some of the extensive testing because several of the materials being used was similar to what the company had previously used in their Cronin implants.
One of the problems that came to light right in the beginning is that the implants began to bleed because of the new watery gel which could bleed into surrounding tissue once placed in the woman’s body. The team reviewed the results and still believed that the bleed was not any more or less than the standard gel they had been using. Because the development of the new implants took off so rapidly Dow was able to ship several samples out to the West Coast for a Plastic Surgeons meeting for review. It was at this time that the surgeons noticed that if the implants were handled for awhile they began to feel oily to the touch. As the implants came out on the market the team started focusing more on how to market the new product rather than resolving the problems that were at hand.
Because Dow Corning was trying to regain its market place, the company felt that if they moved at a very aggressive schedule they could bring back their market share by 50 to 60 percent. They began lowering the cost of the implants, offered rebates and free samples for surgeons. Although they were producing large quantities of the implants they were still faced with many problems. The rejection rate became very high due to floating dirt, weak bags and the walls of the implants were very thin. This created another problem where many of the surgeons had begun to return the implants back to Dow Corning. Even though many were rejected and returned the surgeons liked the product because they were much easier to insert and were more suitable for small-incisions, low-trauma cosmetic procedures. (Contemporary Business Issues, 2000)
Cover-ups had been going on with Dow Corning since its introduction of silicone breast implants to the public in 1965. Before implants were available to the public, Dow Corning left all research aspects of silicone implants to its joint company Dow Chemical. This partnership lasted up until 1992. Dow Corning relied so much on Dow Chemical’s tests that they did not even conduct their own test until after the first implant had been inserted into a woman’s body. The problems really began for Dow in 1972 when five of its own employees went to work for Heyer Schulte, a small medical devices company. They took their knowledge from Dow and manufactured a better implant, giving Dow its first competition since implants had become available. By 1975 Dow’s market share had declined by 35 percent from the new competition. In response to the threat Dow created a task force to create and market a new and improved implant by the end of the year. In order to get a product to market this quick certain things had to be swept aside, one of these things was thorough testing. Dow said that based upon the results of the test done on the first generation of implants that none were necessary for these due to the fact that they were so similar. What Dow failed to say is that the tests on the first implants were inconclusive leaving a lot of questions unanswered about their safety. What made this so scary was that internal meeting notes show there was a concern about "bleed through" with the new implants but no studies were done. At a meeting of plastic surgeons in 1975 the implants were said to have leaked while sitting in their display case. What really put this cover up into perspective were internal memos sent by Dow’s own employees, one of which stated," The thing that is really galling is that I feel like I have been beaten by my own company instead of the competition. To put a questionable lot of mammaries on the market is inexcusable."
Dow’s cover up of a questionable product, is a prime example of corporate greed, with a philosophy of tell the customer what they want to here. Ethically speaking it is still up for debate whether Dow was conducting itself in an improper manner. However, the only facet of the company that was not investigated by an ethical audit was the implant side. Morally this is much more cut and dry. Keith R. McKennon was named CEO of Dow in 1992, the same time the company had come under government scrutiny. He was hired to come in and clean house. This was his forte seeing as how he had done the same thing for Exxon just after their large spill in Alaska. The problem here is that McKennon should have made taking the product off the shelves priority one, not waiting for the FDA to do it for him. He should have realized that his company was playing a major role in the health of thousands of women and taken the initiative to do internal tests and investigations about the implant side of his business. Now McKennon should not be to blame for the companies morality due to the fact that he walked into a burning fire, but he should have looked at the human side of the issues before worrying about the financial.
Widespread reports of adverse reactions to silicone gel-filled implants and a lack of evidence supporting their safety led the Food and Drug Administration (FDA) to order the implants off the market in April 1992. About 110,000 women have silicone gel-filled implants with a polyurethane coating. FDA studies showed that polyurethane foam could break down under human body conditions to form a chemical called TDA, which can cause cancer in animals. They remained available only to women in clinical studies, mostly women seeking breast reconstruction after breast cancer surgery. Saline-filled implants were allowed to remain on the market for all uses.
A study to measure TDA in women with polyurethane implants found that a woman’s risk of cancer from exposure to TDA released by the implant is negligible, about one in a million over a lifetime. FDA considers it unlikely that even one woman would develop cancer from these implants. The study supports the agency’s original recommendation that women who are not having problems should not have the implants removed solely because of concern about cancer from TDA exposure. Replacement of gel with saline filled implants is an option for women contemplating explantation since the saline filled implants lack the potential immunostimulation of the gel filled implants.
While a variety of health problems have been described in association with silicone breast implants, fatigue and pain are the most common complaints in women exposed to silicone. However, the relationship of these symptoms to silicone exposure remains unproven.
Millions of women have received silicone implants, but the long-term safety of the devices has never been studied. Doctors knew that the body produces a fibrous capsule around the implant, and they thought this capsule would protect the body. But researchers have found silicone particles in the tissue surrounding the implant, and even in lymph nodes near the implant. The body produces an immune response to the silicone particles, which could damage joints. Many surgeons say the body produces an immune response to any foreign object placed in the body, but the response is usually benign. The relationship between silicone breast implants and the subsequent development of rheumatic disease remains controversial. To date, epidemiological studies have been negative. The vast majority of women with gel implants exhibit symptoms of chronic fatigue- fibromyalgia like syndrome and diseases like Scleroderma, SLE (Lupus) and Rheumatoid Arthritis.
Silicone Implant Studies compared the rates of immune-related diseases in women with implants versus those without implants have provided reassurance that women with implants are not at a greatly increased risk of these disorders.
In manufacturers’ studies, the events that led to removal of silicone implants from the market made it clear that studies were also needed to answer important safety questions. Implant manufacturers agreed to conduct human trials in three phases: urgent need, adjunct, and core studies. According to Sahar M. Dawisha, MD, a rheumatologist and medical officer who joined FDA’s division of general and restorative devices in April 1993; the purpose of the first phase [urgent need] was to quickly provide implants to women who were already in the process of getting them for breast reconstruction or for another medical reason, and to bridge the time until the adjunct studies were begun. However, the women did have to sign an informed consent form that summarized the risks and benefits of the implants, which had not previously been required. The second phase, studies were intended to follow reconstruction patients for five years to assess short-term safety data, including rates of capsular contracture, rupture, and complications such as infection and collection of blood that may cause swelling, pain and bruising. These studies are open to all women wanting breast reconstruction with implants, because of mastectomy, traumatic injury to the breast, or a disease or congenital disorder causing a severe breast abnormality but do not include augmentation patients. The third phase was intended to determine the full safety and effectiveness profile of the device, including rupture rates, quality-of-life benefits, extent of interference with mammography, and many more safety concerns—including rheumatologic assessments.
According to reports, women with breast implants may have trouble breast-feeding their infants. In a study of 84 new mothers at a Texas hospital, 64 percent of those with breast implants had problems producing enough milk to feed their infants, while only 7 percent of women without implants had such problems. Among women with implants, the type of surgery they had also predicted whether they had problems with breast-feeding: women who had an incision made around their nipple were more likely to have problems producing milk than women who had an incision in the armpit or below the breast, according to the study, published in the January issue of the journal Obstetrics & Gynecology.
According to Nancy Hurst, director of the lactation program and the human milk bank at Texas Children’s Hospital in Houston, "breast surgery most likely disrupts the nerves that are important for successful breast-feeding, normally when the baby begins to suckle, it triggers those nerves to trigger hormones to release milk, and if the nerves are severed, the volume of milk to the child may be reduced." An incision around the nipple, which is done to help make the scar less noticeable, also may sever ducts that drain milk from the mammary gland, according to Dr. Marianne Neifert, a medical consultant to the lactation program at Presbyterian/St. Luke’s Medical Center in Denver. Dr. Neifert added that even if the mother has an adequate milk supply, it may be difficult for the milk to drain into the nipple and eventually, that area of the breast will shut down and stop producing milk. Almost all of the mothers who had the surgery say this wasn’t something they were warned about. According to Dr. John William Little, president of the Plastic Surgery Education Foundation at the American Society of Plastic and Reconstructive Surgeons, the study does not prove that implant surgery interferes with breast-feeding.
Possible Risks of Breast Implants:
•• Autoimmune-like disorders—signs include joint pain and swelling; skin tightness, redness or swelling; swelling of hands and feet; rash; swollen glands or lymph nodes; unusual fatigue; general aching; greater chance of getting colds, viruses and flu; unusual hair loss; memory problems; headaches; muscle weakness or burning; nausea or vomiting; and irritable bowel syndrome.Recent studies have shown, however, that there is not a large increased risk of traditional autoimmune, or connective tissue disease, from silicone gel implants.Fibrositis/fibromyalgia-like disorders (pain, tenderness and stiffness of muscles, tendons and ligaments). In this study, 74% and 65% had complaints of fatigue and pain with 61% meeting the criteria for Chronic Fatigue Syndrome and 49%, Fibromyalgia, with 43% having both; not connective tissue diseases like many studies, primarily funded by the manufacturers and/or plastic surgeons looked for One hundred seventy-six patients with breast prosthetic implants were evaluated. All women were symptomatic and were referred by either attorneys (152) or physicians (24) for rheumatic evaluation. The women ranged in age from 24 to 72 with a mean of 45 years. Indications for surgery were cosmetic (128), cancer (34), and other (14). Implants had been in place for 7 years or more in 120 patients and < 2 years in only 8. Eighty-three women required explantation of their original prostheses, and 63 had new implants inserted of which 47 were silicone and 16 were saline. Capsular contractures were present in 128 women, and documented implant rupture occurred in 67. Sixty-four women underwent manual closed capsulotomies. Of the 63 revisions, 37 resulted in contractures of the new implant.The most frequent symptoms seen in the women were chronic fatigue (77%) cognitive dysfunction (65%), arthralgia (56%), dry mouth (53%), dry eye (50%), alopecia (40%), and dysphagia (35%). The most common findings on physical examination were telangiectasias (60%), erythema of the chest wall (56%), carpal tunnel syndrome (47%), petechiae (46%), lacrimal gland enlargement (26%), thyroid tenderness (22%), thyroid enlargement (21%), and parotid enlargement (18%). Laboratory findings included elevated cholesterol (59%), elevated erythrocyte sedimentation rate (32%), elevated serum immunoglobulin (28%), and positive autonuclear antibody (25%) seen most often. Despite clinical features suggesting Sjöögren’s syndrome, antibodies to Ro (SSA) were seen in only 2 patients, and antibodies to La (SSB) were seen in only 4 patients. Siliconosis is a novel systemic disease with symptoms of chronic fatigue, cognitive dysfunction, sicca syndrome, and arthralgia.
There have been over 13,000-woman involved in a lawsuit on breast implants. The plaintiffs’ claim silicone seeped out through the flexible walls of their implants and triggers several immune system diseases. Mainly the lawsuits are against the companies that produce the implants; which are Dow Chemical and Dow Corning. Dow Chemical which supplies some of the chemicals used in the implants but did not manufacture the implants that were made and sold by Dow Corning a company that is 50 percent owned by Dow Chemical. Several of the women who sued will attempt to prove the silicone breast implants actually made them sick. Ultimately, the pay outs would range from $12,000 to $300,000 each, and Dow Corning estimates that 179,000 women around the world would be covered. An avalanche of claims from women who believed that silicone implants were making them sick drove Dow Corning to seek bankruptcy court protection from creditors in May 1995. The company and lawyers for the women announced a settlement in July. They have been working out the details since then. The negotiations were very contentious. At this point, it is a wonderful time for people to get money to get the medical care they have so badly needed. Nobody is going to get rich on this. Basically one of the most dangerous side affects of the legal medical tangle over breast implants, has been the growing skittishness it inspires among makers and suppliers of the raw material silicone. These makers fear that they could somehow be drawn into liability cases based on these or other silicone devices.
Testimonies
Since the Dow Corning incident many women have come forward to speak up about problems that they have had with breast implants. Some examples such as testimonies from Pat Wingate, Micheline B. Lambert, and Cassandra Brouwer can be accessed through website such as http://www.info-implants.com
The first testimony was from Pat Wingate , she had implants for 9 years and the first 2 years were the worst for her. Within the first 2 years she started to have heart problems and high blood pressure which she never had before. She couldn’t figure out why she had practically lost control of her body. Her arms would just drop to her sides at times and she started to lose the sensation in her left side of her body. She went to her doctor when she had a strange case of the measles. But, after her doctor sent her to a Dow suspected lab they confirmed that she did in fact have the measles. But, for some reason Pat was very concerned and went to the Health Dept. and told them that she had caught a bug from an Airline employee and found out that she didn’t have the measles. She had a reaction to a Toxic chemical which eventually ended up actually making holes in her flesh from the measle like sores.
The second testimony was from Micheline B. Lambert. Now Micheline had her implants done in 1979 which, after 2 years she had to have one of the implants removed and changed. In 1982 the same implant had to be changed twice. Finally in 1987 she finally told the doctor to just remove them.
Ever since her first operation when she had first gotten the implant she had felt sick and still feels sick to this day even after getting the implants removed. When the doctor removed her implants he accidentally cut some nerves in her right side and ever since then she has felt a burning pain in her body as well as her arm feels as if it is paralyzed. She still has problems sleeping at night and can not even eat due to vomiting.
In the third and final testimony from Cassandra Brouwer she started her testimony by saying how women today if the are considering getting breast implants they should gather as much information about them as they can. In the early 1970’s Cassandra was diagnosed with Fibrocystic disease. Her doctor felt that if she had implants it would prevent her from getting cancer. In 1974, she went to a plastic surgeon who used Dow Corning Cronin-type implants series 500 very thin and cheap. When the doctor was done she was very happy with the results that she had seen.
The first month she started to notice that she was feeling pain but, just figured that it was part of the process of having implants. Then, she started to notice that her breasts were becoming very hard and that her left nipple was still sore as it was on the day of the operation. She later started to feel sick such as flu like symptoms, pain in her joints, chills in her head, and bladder and kidney infections constantly, numbness and burning in hands, and an odd smell in her nose. She later found out that she had silicone poisoning and the odd symptoms that she was getting were caused by this poisoning.
Many of these women such as the ones mentioned above have been trying to reach out to other women who have had similar instances in their lives or who are considering breast implants. After reading these testimonies it really makes you think about how safe they really are. But, also we need to realize that there are women that are not only have a lifelong sickness from this but also have died from just having breast implants.